<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004001.pub3" GROUP_ID="PVD" ID="589202070913112358" MERGED_FROM="" MODIFIED="2013-02-26 11:24:50 +0000" MODIFIED_BY="Cathryn Broderick" REVIEW_NO="781" REVMAN_SUB_VERSION="5.2.0 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-02-26 11:24:50 +0000" MODIFIED_BY="Cathryn Broderick">
<TITLE>Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia</TITLE>
<CONTACT MODIFIED="2013-02-26 11:24:50 +0000" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15807" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dirk</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Ubbink</LAST_NAME><POSITION>Physician and Clinical Epidemiologist</POSITION><EMAIL_1>d.ubbink@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Quality Assurance &amp; Process Innovation, and Department of Surgery</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam</ORGANISATION><ADDRESS_1>J1b-215 Academic Medical Centre</ADDRESS_1><ADDRESS_2>Meibergdreef 9, PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1100 DE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-02-26 11:24:50 +0000" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15807" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dirk</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Ubbink</LAST_NAME><POSITION>Physician and Clinical Epidemiologist</POSITION><EMAIL_1>d.ubbink@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Quality Assurance &amp; Process Innovation, and Department of Surgery</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam</ORGANISATION><ADDRESS_1>J1b-215 Academic Medical Centre</ADDRESS_1><ADDRESS_2>Meibergdreef 9, PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1100 DE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="15812" ROLE="AUTHOR"><FIRST_NAME>Hester</FIRST_NAME><LAST_NAME>Vermeulen</LAST_NAME><POSITION>Senior Lecturer, Staff Advisor &amp; Research Co-ordinator</POSITION><EMAIL_1>h.vermeulen@amc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Quality Assurance &amp; Process Innovation</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam &amp; Amsterdam School of Health Professions</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><ADDRESS_2>PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1105 AZ</ZIP><REGION>Noord-Holland</REGION><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5663535</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-02-26 11:20:45 +0000" MODIFIED_BY="Cathryn Broderick">
<UP_TO_DATE>
<DATE DAY="17" MONTH="1" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-02-26 11:21:38 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2013-02-26 11:21:38 +0000" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="26" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>This Cochrane review has been marked stable and will only be updated when new studies are identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-02-26 11:21:16 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-02-26 11:21:16 +0000" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="17" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Searches re-run but no new studies identified. Review search dates updated, minor copy edits made to text. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-02-26 11:21:10 +0000" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="17" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Searches re-run but no new studies identified. Review search dates updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-01-17 10:56:51 +0000" MODIFIED_BY="Karen Welch">
<DATE DAY="24" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Searches re-run and no new studies found. One additional report (Klomp 2006) added to ESES study. Correction made to the analysis results reported in the last paragraph of "Effects of Interventions", Limb salvage. Plain language summary added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-17 10:56:48 +0000" MODIFIED_BY="Karen Welch">
<DATE DAY="8" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-09-25 12:21:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2005"/>
<DESCRIPTION>
<P>No new trials found at last search. Review updated with minor formatting changes and correction to the numbers of amputations in the ESES trial, in accordance with the Comment submitted by Klomp and Steyerberg.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-25 12:27:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Synopsis added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-09-25 12:28:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Feedback and response to feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-01-23 08:22:26 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-01-23 08:22:26 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-01-23 08:22:26 +0000" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-23 08:20:36 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-01-18 10:03:18 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-19 01:36:35 +0100" MODIFIED_BY="[Empty name]">Spinal cord stimulation for patients with chronic critical leg ischaemia who cannot have blood vessel surgery</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-18 10:03:18 +0000" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial disease is relatively common, particularly in late middle age. Blockages in the leg arteries can reduce blood flow in the legs enough to cause fatigue and pain in the muscles when walking (called intermittent claudication). This can become severe and cause critical limb ischaemia which can result in rest pain, leg ulceration, and gangrene that requires amputation. Surgery may improve blood flow but is not possible for everybody. Drugs may be used to relieve pain, improve leg circulation, and treat infection. Another option for patients who cannot have surgery is spinal cord stimulation (SCS). This involves stimulating nerves in the spine to help reduce pain and increase healing of ulcers by improving the local blood circulation in the affected leg. The review authors included five randomised and one controlled clinical trial involving a total of nearly 450 patients. In general the quality of the studies was good. Amputation after 12 months was required less often when SCS was added to standard care. Significant pain relief occurred with and without SCS but patients in the SCS group required fewer pain killers. Overall there was no difference on ulcer healing rates between the two treatment groups. Complications of SCS treatment consisted of problems with initially implanting the electrodes, in 8% of patients, and the need for repeat surgery because of electrode or lead failures in 12% of patients; infections occurred less frequently (3%). The average overall costs at two years were calculated in one study and found to be EUR 36,500 in the SCS group and EUR 28,600 in the conservative treatment alone group.</P>
<P> </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-23 08:20:13 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-10-19 01:06:37 +0100" MODIFIED_BY="[Empty name]">
<P>Patients suffering from inoperable chronic critical leg ischaemia (NR-CCLI) face amputation of the leg. Spinal cord stimulation (SCS) has been proposed as a helpful treatment in addition to standard conservative treatment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-19 01:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>To find evidence for an improvement on limb salvage, pain relief, and the clinical situation using SCS compared to conservative treatment alone.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-23 08:20:13 +0000" MODIFIED_BY="[Empty name]">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched January 2013) and CENTRAL (2012, Issue 12).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-10-19 01:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled studies comparing the addition of SCS with any form of conservative treatment to conservative treatment alone in patients with NR-CCLI.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Both authors independently assessed the quality of the studies and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-28 16:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>Six studies comprising nearly 450 patients were included. In general the quality of the studies was good. No study was blinded due to the type of intervention.</P>
<P>Limb salvage after 12 months was significantly higher in the SCS group (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.56 to 0.90; risk difference (RD) -0.11, 95% CI -0.20 to -0.02). Significant pain relief occurred in both treatment groups, but was more prominent in the SCS group where the patients required significantly less analgesics. In the SCS group, significantly more patients reached Fontaine stage II than in the conservative group (RR 4.9, 95% CI 2.0 to 11.9; RD 0.33, 95% CI 0.19 to 0.47). Overall, no significantly different effect on ulcer healing was observed with the two treatments.</P>
<P>Complications of SCS treatment consisted of implantation problems (9%, 95% CI 4 to 15%) and changes in stimulation requiring re-intervention (15%, 95% CI 10 to 20%). Infections of the lead or pulse generator pocket occurred less frequently (3%, 95% CI 0 to 6%). Overall risk of complications with additional SCS treatment was 17% (95% CI 12 to 22%), indicating a number needed to harm of 6 (95% CI 5 to 8).</P>
<P>Average overall costs (one study) at two years were EUR 36,500 (SCS group) and EUR 28,600 (conservative group). The difference (EUR 7900) was significant (P &lt; 0.009).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-10-19 01:29:19 +0100" MODIFIED_BY="[Empty name]">
<P>There is evidence to favour SCS over standard conservative treatment alone to improve limb salvage and clinical situations in patients with NR-CCLI. The benefits of SCS must be considered against the possible harm of relatively mild complications and the costs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-23 08:20:36 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-19 03:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment of chronic critical limb ischaemia (CCLI) is a challenge in vascular medicine since comorbidity (the presence of two or more coexisting medical conditions) and mortality are high due to the presence of systemic atherosclerosis. The natural history of CCLI is difficult to describe because of differences in definitions used and the proportion of patients who are revascularised. It is estimated that 10% to 30% of patients with CCLI will die within six months and another 25% to 35% will undergo a major amputation (<LINK REF="REF-TASC-2000a" TYPE="REFERENCE">TASC 2000a</LINK>). Revascularisation (surgical restoration of blood flow to an organ) is the therapy of choice in CCLI patients, used to relieve ischaemic rest pain, heal ischaemic ulcers or gangrene, and to avoid major (foot or higher) amputation (<LINK REF="REF-TASC-2000b" TYPE="REFERENCE">TASC 2000b</LINK>). Nevertheless, for some patients vascular surgery has no realistic chance of success despite technical progress, an aggressive surgical approach, and repetitive reconstructions. Their pain is often disabling, adversely affects their quality of life and severely limiting their activity levels.</P>
<P>The only option for these patients with non-reconstructable chronic critical leg ischaemia (NR-CCLI), so far, is conservative treatment consisting of analgesics, vasodilators, and anticoagulants; before amputation ultimately becomes necessary. Alternative or additional therapies have been sought to improve limb salvage and quality of life. These include surgical interruption of the sympathetic nerves to promote vasodilation and relieve pain (sympathectomy), or spinal cord stimulation (SCS). SCS has been proposed as an aid in the management of chronic, intractable pain of the trunk or limbs. Several pre-clinical and clinical studies using SCS have been performed to investigate potential beneficial effects such as reduction in amputation rate, pain relief, and healing of ulcers. The most desired effect is limb salvage.</P>
<P>Cook et al were the first investigators to use SCS in patients with peripheral vascular disease (<LINK REF="REF-Cook-1976" TYPE="REFERENCE">Cook 1976</LINK>). They reported a striking relief of pain and increased healing of ulcers. In some publications SCS appeared to provide good-to-excellent pain control in 60% to 82% of patients (<LINK REF="REF-Bunt-1991" TYPE="REFERENCE">Bunt 1991</LINK>; <LINK REF="REF-Claeys-1998" TYPE="REFERENCE">Claeys 1998</LINK>; <LINK REF="REF-Fiume-1989" TYPE="REFERENCE">Fiume 1989</LINK>; <LINK REF="REF-Horsch-1994" TYPE="REFERENCE">Horsch 1994</LINK>; <LINK REF="REF-Jacobs-1990" TYPE="REFERENCE">Jacobs 1990</LINK>; <LINK REF="REF-Kumar-1997" TYPE="REFERENCE">Kumar 1997</LINK>; <LINK REF="REF-Mingoli-1993" TYPE="REFERENCE">Mingoli 1993</LINK>; <LINK REF="REF-Rickman-1994" TYPE="REFERENCE">Rickman 1994</LINK>; <LINK REF="REF-Tesfaye-1996" TYPE="REFERENCE">Tesfaye 1996</LINK>). A reduction in use of oral pain medications was found (<LINK REF="REF-Mingoli-1993" TYPE="REFERENCE">Mingoli 1993</LINK>; <LINK REF="REF-Spiegelmann-1991" TYPE="REFERENCE">Spiegelmann 1991</LINK>; <LINK REF="REF-Tesfaye-1996" TYPE="REFERENCE">Tesfaye 1996</LINK>) whilst others described an improvement in claudication distance (<LINK REF="STD-Tallis-1983" TYPE="STUDY">Tallis 1983</LINK>). Increases in skin temperature have been registered by thermographic recordings and measurements of skin temperature (<LINK REF="REF-Augustinsson-1985" TYPE="REFERENCE">Augustinsson 1985</LINK>; <LINK REF="REF-Broseta-1986" TYPE="REFERENCE">Broseta 1986</LINK>). Improvements in activities of daily living were also shown (<LINK REF="REF-Fiume-1989" TYPE="REFERENCE">Fiume 1989</LINK>; <LINK REF="REF-Linderoth-1992" TYPE="REFERENCE">Linderoth 1992</LINK>; <LINK REF="REF-Rickman-1994" TYPE="REFERENCE">Rickman 1994</LINK>; <LINK REF="REF-Spiegelmann-1991" TYPE="REFERENCE">Spiegelmann 1991</LINK>; <LINK REF="REF-Tesfaye-1996" TYPE="REFERENCE">Tesfaye 1996</LINK>). These results have been confirmed by other studies (<LINK REF="REF-Augustinsson-1985" TYPE="REFERENCE">Augustinsson 1985</LINK>; <LINK REF="REF-Broseta-1986" TYPE="REFERENCE">Broseta 1986</LINK>; <LINK REF="REF-Jacobs-1990" TYPE="REFERENCE">Jacobs 1990</LINK>).</P>
<P>Postulated beneficial effects of SCS on the ischaemic leg could be attributed to an improvement in the microcirculatory status of the limb. The nutrition of the skin is determined by the peripheral microcirculatory blood flow. Several authors saw an increase in direct and indirect parameters of skin microcirculation, such as capillary flow and density of capillaries perfused (<LINK REF="REF-Jacobs-1990" TYPE="REFERENCE">Jacobs 1990</LINK>), as well as skin temperature of the foot (<LINK REF="REF-Augustinsson-1985" TYPE="REFERENCE">Augustinsson 1985</LINK>; <LINK REF="REF-Broseta-1986" TYPE="REFERENCE">Broseta 1986</LINK>). Local transcutaneous oxygen tension (TcpO<SUB>2</SUB>) was suggested as a predictive factor of success (<LINK REF="REF-Galley-1994" TYPE="REFERENCE">Galley 1994</LINK>; <LINK REF="REF-Gersbach-1997" TYPE="REFERENCE">Gersbach 1997</LINK>; <LINK REF="REF-Kumar-1997" TYPE="REFERENCE">Kumar 1997</LINK>; <LINK REF="REF-Spincemaille-2001" TYPE="REFERENCE">Spincemaille 2001</LINK>; <LINK REF="REF-Ubbink-1999" TYPE="REFERENCE">Ubbink 1999</LINK>). Doppler ultrasound recordings showed a tendency toward normalisation of the pulse wave morphology (<LINK REF="REF-Broseta-1986" TYPE="REFERENCE">Broseta 1986</LINK>). However, few of the above-mentioned studies were randomised or controlled.<B>
<BR/>
</B>
</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-10-19 01:57:03 +0100" MODIFIED_BY="[Empty name]">
<P>To identify and summarise the evidence for the effectiveness of SCS in the treatment of patients suffering from non-reconstructable chronic critical leg ischaemia (NR-CCLI) as compared with conservative treatment alone. This usually consists of analgesic, vasodilatory or anticoagulant medications and local wound care.</P>
<SUBSECTION>
<HEADING LEVEL="2">Primary objective</HEADING>
<P>To assess the effect of SCS on limb salvage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objective</HEADING>
<P>To assess the effect of SCS on pain relief, wound healing, quality of life, costs and complications caused by SCS.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-23 08:20:36 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-01-18 10:04:32 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-19 01:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) evaluating the effectiveness of SCS in patients with NR-CCLI. Controlled clinical trials (CCTs) were also included as it was expected that the number of RCTs would be limited.</P>
<P>To be in agreement with the reporting standards definition of CCLI (<LINK REF="REF-TASC-2000c" TYPE="REFERENCE">TASC 2000c</LINK>), these studies had to present an objective measure of peripheral arterial disease, such as a systolic ankle blood pressure &lt; 50 mm Hg, a toe blood pressure &lt; 30 mm Hg, a TcpO2 &lt; 30 mm Hg, to ensure that the clinical manifestations of CCLI were indeed caused by peripheral arterial disease.</P>
<P>Studies with patients suffering from severe peripheral arterial disease according to their peripheral pressures but without symptoms of CCLI (subcritical ischaemia) were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-19 02:03:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Men and women aged over 18 years with atherosclerotic non-reconstructable chronic critical leg ischaemia (NR-CCLI).</P>
<P>Chronic critical leg ischaemia was defined according to the TransAtlantic inter-Society Consensus document (<LINK REF="REF-TASC-2000c" TYPE="REFERENCE">TASC 2000c</LINK>), which is based on the clinical symptoms predominantly caused by peripheral arterial disease (that is ischaemic rest pain and ulceration).</P>
<P>Non-reconstructability was defined as the situation in which the treating physician saw no surgical options for the patient to treat the critically ischaemic leg at the time of trial inclusion. This can occur when no crural arteries can be found on the angiogram, as potential sites for a distal bypass procedure; no suitable veins are available as bypass material; or when the patient's condition precludes an operation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>The term 'atherosclerotic' excluded patients suffering from critical leg ischaemia solely due to non-atherosclerotic vascular diseases, like Raynaud's disease or Buerger's disease. Inclusion of these patients would cause an undesired heterogeneity of the study population.</P>
<P>Milder forms of leg ischaemia, in particular intermittent claudication, are not considered suitable for SCS treatment because this condition does not generally require vascular reconstruction.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-19 02:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>SCS treatment was compared with other forms of non-surgical treatment, such as analgesics, vasodilatory or anticoagulant medications (including prostaglandins) and local wound care.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-18 10:04:32 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-01-18 10:04:24 +0000" MODIFIED_BY="[Empty name]">
<P>Limb salvage, which ended the moment a major (foot or higher) amputation took place.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-01-18 10:04:29 +0000" MODIFIED_BY="[Empty name]">
<P>Pain relief, wound healing, SCS complications, quality of life, and costs; according to the scales used in the various articles.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-23 08:20:36 +0000" MODIFIED_BY="[Empty name]">
<P>Searches were not limited by language or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-01-23 08:20:36 +0000" MODIFIED_BY="[Empty name]">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched January 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 12, part of <I>The Cochrane Library</I>, (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A>) section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<P>For the original review, the authors searched MEDLINE, EMBASE, and CINAHL using a search strategy devised from the key words listed in (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-19 02:09:25 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted authors of included RCTs or CCTs for additional data or unpublished studies, and searched the bibliographies of the trials identified through the search process. We also approached the research centre of the major manufacturer of neurostimulators (Bakken Research Centre, Maastricht, The Netherlands). They were not aware of any recently finished or ongoing studies at the time of updating the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-19 02:16:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>The titles and abstracts of references identified by the search were screened independently by two authors (DU, HV) for their potential relevance and design. Full versions of articles were obtained and checked independently to identify those that met the inclusion criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>The methodological quality of each trial was systematically assessed by the same two authors (DU, HV). A third independent referee (ASG) from the Department of Clinical Epidemiology and Biostatistic assessed the two trials co-authored by DU. The assessment was performed according to the Dutch Cochrane Centre list of factors (<LINK REF="REF-Dutch-CC" TYPE="REFERENCE">Dutch CC</LINK>) relating to internal and external validity. This list includes the following.</P>
<P>1. Was allocation of intervention randomised?<BR/>2. Was allocation concealed from the researcher who included the patients?<BR/>3. Was the proportion of participants with completed follow up &gt; 80%?<BR/>4. Was an intention-to-treat analysis used?<BR/>5. Were all participants blinded to the intervention?<BR/>6. Were all healthcare workers blinded for the intervention?<BR/>7. Were all outcome assessors blinded for the intervention?<BR/>8. Were both groups comparable at baseline?<BR/>9. Were both groups, apart from the investigated intervention, treated the same?<BR/>10. Are the results of this trial valid and applicable?<BR/>11. Was the sample size based on a proper a priori calculation?</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection and extraction</HEADING>
<P>Details of the studies selected were extracted and summarised independently by two authors (DU, HV) using a data extraction sheet from the Dutch Cochrane Centre (<LINK REF="REF-Dutch-CC" TYPE="REFERENCE">Dutch CC</LINK>). If data were missing from reports of trials, attempts were made to contact the authors to obtain the missing information. Trials published in duplicate were included only once. Using the Dutch Cochrane Centre data form, the following information was captured:</P>
<P>(1) characteristics of the trial (design, method of randomisation, withdrawals and dropouts, funding source);<BR/>(2) trial participants (gender, age, wound characteristics, comorbidity, co-interventions);<BR/>(3) intervention (SCS);<BR/>(4) comparison intervention (non-surgical therapies);<BR/>(5) primary outcome measure (limb salvage);<BR/>(6) secondary outcome measures (pain relief, wound healing, quality of life, complications, costs, TcpO2);<BR/>(7) results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Quantitative data were entered into the Cochrane RevMan 4.1 software and analysed using MetaView. For each trial and outcome, summary estimates of treatment effect (with 95% confidence intervals (CI)) were calculated for each comparison. For dichotomous outcomes the risk ratio (RR) and risk reduction (RD) were calculated (<LINK REF="REF-Deeks-1998" TYPE="REFERENCE">Deeks 1998</LINK>). For continuous outcomes the mean difference (MD), or standardised mean difference (SMD), was used, where appropriate.</P>
<P>Analyses were performed for the studies, separately and combined. Stratification for the presence of diabetes mellitus could not be performed because too little information was given as to the endpoints in diabetic patients. Results of clinically homogeneous trials (trials for which the participants, interventions, outcome measures, and timing of the follow-up measurements were considered to be similar enough) were combined using a fixed-effect model. A random-effects model was used in the case of statistical heterogeneity (assessed by visual inspection of the forest plots) and the availability of at least five studies. No pooling could be performed when an endpoint was addressed by only one study or when the study did not mention the standard deviations.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-18 10:06:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-19 03:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>Nineteen reports were found on the basis of the inclusion criteria, nine of which were excluded. Of the nine excluded studies: four were excluded because they were not RCTs or CCTs (<LINK REF="STD-Claeys-1997b" TYPE="STUDY">Claeys 1997b</LINK>; <LINK REF="STD-Palombo-1995" TYPE="STUDY">Palombo 1995</LINK>; <LINK REF="STD-Petrakis-2000" TYPE="STUDY">Petrakis 2000</LINK>; <LINK REF="STD-Tallis-1983" TYPE="STUDY">Tallis 1983</LINK>). One reference was only a description of the study design (Klomp 1995), and one included reconstructable patients (<LINK REF="STD-Guarnera-1994" TYPE="STUDY">Guarnera 1994</LINK>). Three references were duplicate publications (<LINK REF="STD-Claeys-1997a" TYPE="STUDY">Claeys 1997a</LINK>; <LINK REF="STD-Claeys-1998b" TYPE="STUDY">Claeys 1998b</LINK>; <LINK REF="STD-Claeys-1999" TYPE="STUDY">Claeys 1999</LINK>).</P>
<P>The resulting 10 papers, all published since 1994, described six trials. There were five national studies including: one Belgian (<LINK REF="STD-Suy-1994" TYPE="STUDY">Suy 1994</LINK>), one Swedish (<LINK REF="STD-Jivegard-1995" TYPE="STUDY">Jivegard 1995</LINK>), one German (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>), and two Dutch studies (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>; <LINK REF="STD-Spincemaille-2000a" TYPE="STUDY">Spincemaille 2000a</LINK>); and one international study, SCS-EPOS, (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>). Data were obtained for inclusion in the review. The study sizes varied from 37 to 120 patients, adding up to a total of 444 participating patients. Five out of the 10 papers (<LINK REF="REF-Klomp-1999" TYPE="REFERENCE">Klomp 1999</LINK>; <LINK REF="REF-Klomp-2006" TYPE="REFERENCE">Klomp 2006</LINK>; <LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>; <LINK REF="REF-Spincemaille-2000c" TYPE="REFERENCE">Spincemaille 2000c</LINK>; <LINK REF="REF-Ubbink-1999" TYPE="REFERENCE">Ubbink 1999</LINK>) focused on the Dutch ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>), each addressing a different endpoint or aspect. In particular, Klomp (<LINK REF="REF-Klomp-1999" TYPE="REFERENCE">Klomp 1999</LINK>), described overall limb salvage, ulcer healing, and costs; <LINK REF="REF-Klomp-2006" TYPE="REFERENCE">Klomp 2006</LINK> compared costs and effectiveness; Spincemaille (<LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>), focused on the effects on pain and quality of life; Spincemaille (<LINK REF="REF-Spincemaille-2000c" TYPE="REFERENCE">Spincemaille 2000c</LINK>) addressed the complications of SCS; and Ubbink (<LINK REF="REF-Ubbink-1999" TYPE="REFERENCE">Ubbink 1999</LINK>) described the effects on TcpO<SUB>2</SUB>.</P>
<P>All studies included patients suffering from non-reconstructable critical leg ischaemia, that is having either ischaemic rest pain or ulcers smaller than 3 cm in diameter and on the basis of their clinical symptoms, peripheral blood pressure parameters and angiographic findings. The percentage of patients having only ischaemic rest pain ranged from 24% to 49% among the studies. In the German study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) only patients with ischaemic ulcers were included; while in the Belgian study (<LINK REF="STD-Suy-1994" TYPE="STUDY">Suy 1994</LINK>) 11 patients with Buerger's disease were also enrolled. These 11 patients were excluded from the limb salvage meta-analysis.</P>
<P>In all studies, patients received control treatment with or without SCS. In the German study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) and SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>), a period of test stimulation was applied before definitive implantation of the SCS pulse generator. Control treatment consisted of optimum conservative treatment (local wound care, analgesics, anticoagulants, and antibiotics, if deemed necessary), which was comparable among the studies. In the German study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) additional prostaglandin therapy was given to both groups.</P>
<P>In two studies, the transcutaneous oxygen (TcpO2) measurements were used for patient classification. In the ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) a subgroup analysis was performed after classification of the patients on the basis of their baseline TcpO<SUB>2</SUB> values. The SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) compared: patients treated with SCS who matched certain TcpO<SUB>2</SUB> and stimulation criteria; patients receiving SCS but not matching these criteria; and patients who received control treatment as SCS was regarded not to be a useful option, either on the basis of the initial TcpO<SUB>2</SUB> or an insufficient response to a period of test stimulation.</P>
<P>All studies used limb salvage (major amputation rate after 12 months) as the primary endpoint. Furthermore, in most studies pain relief and Fontaine stage (<LINK REF="REF-Fontaine-1954" TYPE="REFERENCE">Fontaine 1954</LINK>) were scored, and in some studies complications of SCS and quality of life were also noted.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-19 02:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>All studies were randomised trials except for the SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>), which was a controlled clinical trial. This study refrained from randomisation in order to obtain sufficient patients for evaluation as it was anticipated from the experience of the previous studies that the number of eligible, non-reconstructable patients with chronic limb ischaemia would be limited. To pursue a randomised design would require a very long study duration, which was considered not to be feasible. Nevertheless, this study was included because it comprised the same target population, and the therapeutic decision making reflected the actual clinical situation.</P>
<P>Randomisation in the ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) was performed by means of a random numbers table via an independent randomisation institute. The other studies provided no specific allocation information. Sample size calculation was performed only in the Klomp (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) and SCS-EPOS (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) studies.</P>
<P>Blinding of the treating physicians and patients was impossible due to the nature of the treatment, which is based on the correct location of the electrode so that the paraesthesiae (tingling sensation) induced by the electrical stimulation reaches the painful area. This prerequisite requires communication between physician and patient. The effect authors were, therefore, also not blinded.</P>
<P>In every study the groups were comparable at baseline as to the patients' demographic and risk factors. In most studies a considerable number of patients died during follow up. This was due to the fact that the studies included elderly patients who suffered from generalised atherosclerosis, which reduces life expectancy. Drop outs due to death during follow up were accounted for in all studies. The follow up on the remaining patients was (nearly) complete in all studies. In all RCTs an intention-to-treat analysis was performed. In the ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) an additional per protocol analysis was done because 13% of the patients received suboptimal stimulation.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-18 10:06:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Limb salvage</HEADING>
<P>The Belgian (<LINK REF="STD-Suy-1994" TYPE="STUDY">Suy 1994</LINK>), Swedish (<LINK REF="STD-Jivegard-1995" TYPE="STUDY">Jivegard 1995</LINK>), German (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>), ESES (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>), and SCS-EPOS (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) studies did not show a significant difference between groups in amputation frequency after 12, 18, or 24 months of follow up; although all studies showed a trend towards a better amputation-free salvage in the SCS group (for example <LINK REF="STD-Spincemaille-2000a" TYPE="STUDY">Spincemaille 2000a</LINK>: P = 0.08). This trend was stronger in a subgroup of patients selected by their initial TcpO<SUB>2</SUB> as compared to the overall result (P = 0.17 versus P = 0.47, respectively) (<LINK REF="REF-Ubbink-1999" TYPE="REFERENCE">Ubbink 1999</LINK>). In the SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>), the difference in cumulative limb salvage was significantly better in the patients treated with SCS (P = 0.003), and in particular in a subgroup selected based on their initial TcpO<SUB>2</SUB> and response to test stimulation (P = 0.002). In a subgroup of normotensive patients, the amputation rate after 18 months was lower in the SCS group (P = 0.045) (<LINK REF="STD-Jivegard-1995" TYPE="STUDY">Jivegard 1995</LINK>).</P>
<P>The baseline risk of amputation was about 50% in all studies (ranging from 46% to 64%), except in the Claeys study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) in which it was 20%.</P>
<P>Pooling of the results yielded a significant effect of SCS after 12 months (RR 0.74, 95% CI 0.57 to 0.94; RD -0.11, 95% CI -0.20 to -0.02). This effect did not change substantially after exclusion of the single non-randomised SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) (RR 0.78, 95% CI 0.58 to 1.04; RD -0.09, 95% CI -0.19 to 0.01), or the Claeys study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) which included only patients in Fontaine stage IV (RR 0.73, 95% CI 0.56 to 0.94; RD 0.13, 95% CI 0.02 to 0.23). This result means that nine patients need to be treated to prevent one more major amputation (NNT 9, 95% CI 5 to 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain relief</HEADING>
<P>When judged with the visual analogue scale (VAS) (<LINK REF="REF-Carlsson-1983" TYPE="REFERENCE">Carlsson 1983</LINK>), pain relief was found to be significantly better in the SCS group after three months (P = 0.0004) (<LINK REF="STD-Spincemaille-2000a" TYPE="STUDY">Spincemaille 2000a</LINK>) and 12 months (P &lt; 0.01) (<LINK REF="STD-Jivegard-1995" TYPE="STUDY">Jivegard 1995</LINK>). However, in the ESES study (<LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>) a highly significant reduction in pain scores (from a mean of 50 to 25) during follow up was found but with no difference between the two treatment groups.</P>
<P>The pain rating index (PRI), as part of the McGill pain questionnaire (<LINK REF="REF-Melzack-1975" TYPE="REFERENCE">Melzack 1975</LINK>), also showed a significant decrease during follow up in both groups (<LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>). During follow up, patients receiving SCS used significantly less non-narcotic and narcotic analgesics than the patients treated conservatively (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>; <LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>), as measured with the medication quantification scale (<LINK REF="REF-Masters_x002d_Steed-1992" TYPE="REFERENCE">Masters-Steed 1992</LINK>).</P>
<P>In patients who underwent a major amputation during the follow-up period, the VAS score declined significantly (P &lt; 0.001) in both treatment groups. This held also for the PRI (P = 0.001). Thus, pain relief in amputated patients was substantially better than in non-amputated patients, irrespective of the treatment (<LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>).</P>
<P>Pooling could not be performed due to missing standard deviations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical improvement</HEADING>
<P>In the studies of Claeys (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) and Suy (<LINK REF="STD-Suy-1994" TYPE="STUDY">Suy 1994</LINK>), the number of patients whose clinical stage improved from critical leg ischaemia to claudication was significantly higher in the SCS than in the conservative group (P = 0.0014) (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>). When pooled, the RR was 4.9 (95% CI 2.0 to 11.9) and the RD 0.33 (95% CI 0.19 to 0.47). This means three patients have to be treated with SCS for one patient to reach Fontaine stage II (NNT 3, 95% CI 2 to 5).</P>
<P>Two studies reported on the healing of ischaemic ulcers (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>; <LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>). Claeys found SCS had a significantly better effect on wound healing than conservative treatment (P = 0.013), whereas Klomp (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) found no significant difference. Pooling resulted in no significant difference between the two treatment modalities.</P>
<P>When subgroups of patients with and without hypertension were compared for ulcer healing, Claeys (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) found a significantly better effect of SCS than conservative treatment in normotensives, whereas Suy (<LINK REF="STD-Suy-1994" TYPE="STUDY">Suy 1994</LINK>) found a better SCS effect in hypertensives.</P>
<P>No significant differences in treatment effects were found between diabetic and non-diabetic patients (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>; <LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ankle brachial pressure index (ABPI)</HEADING>
<P>The study of Claeys (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) showed a significant difference in ABPI change during follow up: 0.03, an increase of 10% compared to baseline in the SCS group; and -0.058, a decrease of 17% compared to baseline in the conservative treatment group (P &lt; 0.02). Only SCS patients who achieved complete ulcer healing showed a significant ABPI increase of 0.09 (P &lt; 0.01). However, Jivegard (<LINK REF="STD-Jivegard-1995" TYPE="STUDY">Jivegard 1995</LINK>) found no change in ABPI in either groups during treatment. Pooling could not be performed due to missing standard deviations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>In the SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) an SF-12 questionnaire was used during follow up only for the SCS-treated patients. This showed no worsening of the overall quality of life.<BR/>The ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>), described by Spincemaille (<LINK REF="REF-Spincemaille-2000b" TYPE="REFERENCE">Spincemaille 2000b</LINK>), applied the Nottingham health profile (NHP) and the Euroqol in both treatment groups. The overall score of the NHP decreased (that is quality of life improved) during follow up in both treatment groups. The mobility score of the NHP was significantly better in the patients treated with SCS (P &lt; 0.01). In case of an amputation, mobility was reduced and not influenced by rehabilitation programmes. The Euroqol also showed an improvement after 12 months, in the SCS and conservative groups (SCS: from 54 to 11; conservative: from 51 to 10). After amputation these scores worsened to 66 and 61, respectively, but recovered over a period of several months to reach similar values to those of non-amputated patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Local transcutaneous oxygen tension (TcpO<SUB>2</SUB>)</HEADING>
<P>In the Claeys study (<LINK REF="STD-Claeys-1996" TYPE="STUDY">Claeys 1996</LINK>) the TcpO<SUB>2</SUB> (measured with a Hellige device), which was comparable at baseline (SCS: 10 mm Hg, conservative: 12 mm Hg), was significantly higher in the SCS group after 12 months of treatment (21 mm Hg versus 11 mm Hg; P &lt; 0.001).</P>
<P>In the ESES study (<LINK REF="REF-Ubbink-1999" TYPE="REFERENCE">Ubbink 1999</LINK>) TcpO<SUB>2</SUB> (using a radiometer device) was similar at baseline (10 mm Hg in both groups) and increased significantly (P &lt; 0.05) during follow up, but was not significantly different between groups. This was found carrying forward the results before amputation.</P>
<P>Only the mean TcpO<SUB>2</SUB> results after 12 months could be pooled. Using a random-effects model, no significant difference could be detected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Complications</HEADING>
<P>No differences in mortality were observed. Usually only the complications of SCS treatment were mentioned. In the ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) side effects of medical treatment in the conservative group were upper gastrointestinal bleeding (three), nausea (seven), and dizziness (two); while in the SCS group duodenal perforation (one), nausea (two), and pruritus (itching) (one) were recorded.</P>
<P>Initial implantation problems (technical or anatomical problems causing failure of positioning the electrode in the epidural space) were recorded in two trials. In the SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>) two out of a total of 75 patients could not have electrodes implanted. In the ESES study (<LINK REF="REF-Spincemaille-2000c" TYPE="REFERENCE">Spincemaille 2000c</LINK>) this was nine out of 60 patients. After pooling, the risk of implantation problems was 8% (random-effects model: 95% CI -6 to 22%), implying that in every 12 patients an implantation problem could be expected.</P>
<P>All trials reported the number of changes in stimulation requiring a surgical re-intervention, which could be because of dislocation of the electrode or fracture of the lead. Multicentre trials showed the highest complication incidence. Pooling resulted in a risk of 12% (random-effects model: 95% CI 5 to 20%). Infections of the lead or subcutaneous pulse generator pocket occurred less frequently. The pooled risk from the six studies was 3% (95% CI 0 to 6%). Depletion of the battery within 18 months of follow up also occurred: in five patients in the SCS-EPOS study (<LINK REF="STD-Amann-2003" TYPE="STUDY">Amann 2003</LINK>), and in three patients in the ESES study (<LINK REF="REF-Spincemaille-2000c" TYPE="REFERENCE">Spincemaille 2000c</LINK>).</P>
<P>The overall number of complications of SCS treatment (comprising infection of lead or impulse generator pocket, dislocation or breakage of the lead, and early depletion of the battery) were pooled over the six trials. The overall complication risk was 0.18 (random-effects model: 95% CI 0.03 to 0.32), indicating a number needed to harm of 6 (95% CI 3 to 33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Costs</HEADING>
<P>Only the ESES study (<LINK REF="STD-ESES" TYPE="STUDY">ESES</LINK>) included a cost comparison (<I>see </I>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The average overall costs of hospitalisation, rehabilitation, operative procedures, stimulator, outpatient care, professional home care, medication and non-medical costs at two years were EUR 36,500 in the SCS group and EUR 28,600 in the conservative group. This was a significant difference (P &lt; 0.009). After adjustment for mortality these figures were EUR 31,340 (SCS) and EUR 23,780 (conservative) (P &lt; 0.002).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-19 03:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>As compared with the large total number of publications on SCS for non-reconstructable critical leg ischaemia (CLI), only a few randomised studies have been performed. One of the reasons may be the limited number of patients with CLI regarded as non-reconstructable, and thus considered eligible candidates for such a trial, a fact illustrated by the relatively small study sizes of randomised studies. The chance of publication bias is regarded as small, considering that the manufacturers of nearly all SCS devices are keeping track of all studies that are or have been performed on SCS in this patient group.</P>
<P>Due to the non-blinded character of the studies, limb salvage results could be biased if amputations were postponed in SCS-treated patients. However, progressive necrosis (localised tissue death) with imminent sepsis (infection) and intractable pain despite maximum analgesic therapy (which was allowed in both treatment groups) were the absolute indications for an amputation. Hence, it is not likely this has had a significant influence on eventual limb salvage.</P>
<P>The ongoing discussion about the definition of critical leg ischaemia and non-reconstructability further obscures the indication for such a therapy. Furthermore, this patient group has a limited life expectancy due to their increased age and the presence of generalised atherosclerosis, which limits the benefit of any treatment. On the other hand, this patient group faces the ultimate prospect of amputation. Hence, any alternative treatment option with a limb saving and pain relieving potential deserves proper evaluation.</P>
<P>The included trials all focused on limb salvage, clinical improvement, and complications, comparing SCS with optimum non-surgical therapy. Only a few studies addressed quality of life and cost. Although blinding was impossible, the overall quality of the studies was good. The results of some (secondary) endpoints (for example ABPI, TcpO<SUB>2</SUB>) are difficult to interpret as they are influenced by the loss from the trial of patients undergoing an amputation during follow up, which leaves only the 'better' patients. This positively biases the results.</P>
<P>None of the individual RCTs revealed a significant beneficial effect on limb salvage. Probably the individual studies, which took approximately five years for each to be completed, tended to be underpowered. To include a larger number of patients that matched the strict inclusion criteria would have taken too much time. However, after pooling a positive effect on limb salvage was found at the cost of a significantly higher number of (correctable) complications and (probably) higher costs. Additionally, there is some evidence of a beneficial effect on ulcer healing and pain relief. The finding that TcpO<SUB>2</SUB>, but not ABPI, seems to increase during follow up suggests SCS treatment mainly acts on the local microcirculation. Pain relief and ulcer healing may also improve walking ability, which may further enhance local circulation.</P>
<P>The general quality of life seemed to remain unchanged. Apparently this is influenced by other major factors in life, or the questionnaires used are too insensitive to measure specific changes due to the treatment of CLI. To date, we are still in want of specific questionnaires to appreciate quality of life in CLI. A major amputation can still be considered as an alternative treatment because it leads to good pain relief, albeit at the cost of a (temporary) reduction in mobility.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-19 03:19:07 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-19 03:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>There is evidence that SCS is better than conservative treatment alone in order to achieve amputation risk reduction, pain relief, and improvement of the clinical situation in patients with non-reconstructable chronic stable critical limb ischaemia. The effect of SCS appears to be stronger after further patient selection on the basis of a beneficial local transcutaneous oxygen tension (TcpO<SUB>2</SUB>) and test stimulation period. This beneficial effect should be weighed against the harm SCS may cause (implantation failures and relatively mild complications). In addition, the impact of SCS treatment on healthcare budgets needs to be considered.</P>
<P>If pain relief is the primary goal, a major amputation may be the treatment of choice in patients with an already limited mobility.</P>
<P>The higher complication rate, as found in multicentre studies enrolling few patients per centre, indicates that this treatment should be reserved to specialised centres which have the facilities and expertise to provide SCS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-10-19 03:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>Given the present evidence, SCS treatment appears beneficial to a small subgroup of CLI patients. Despite the expected low inclusion rates, randomised controlled trials with clear inclusion criteria may further elucidate which patients may benefit from SCS therapy. Quality of life, cost-effectiveness, and pain assessment in patients after an amputation should be among the endpoints. To assess the quality of life, the SF36 (<LINK REF="REF-Ware-1998" TYPE="REFERENCE">Ware 1998</LINK>) is recommended as the best validated general questionnaire while still in want of a specific questionnaire for CLI.</P>
<P>Inclusion criteria should aim at including patients who are most likely to benefit from SCS treatment. A period of test stimulation and TcpO<SUB>2</SUB> monitoring to assess the local circulation appear useful for this purpose. Further research is required in this area. Usually effect parameters such as the TcpO<SUB>2</SUB> are calculated during follow up without carrying forward the data obtained from those who previously underwent an amputation. This leaves only the participants who retained their leg and probably had better oxygenation. This bias should be avoided.</P>
<P>Given the evidence that limb salvage obtained with SCS is comparable to (distal) bypass surgery, other indications for experimental SCS treatment may also be considered (for example reconstructable CLI) and compared with less promising surgical interventions such as very distal or infrainguinal prosthetic bypass procedures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-17 11:09:33 +0000" MODIFIED_BY="[Empty name]">
<P>We thank Mrs Heather Maxwell for her helpful and prompt assistance in the preparation of the protocol and review, Mrs Astrid Goossens (AG) for her assistance in the quality assessment and the Bakken Research Center Maastricht for supplying the data from the European SCS-EPOS trial.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Bakken Research Centre sponsored the principal investigator (DU) as 'quality officer' for the duration of the Spinal Cord Stimulation European Peripheral Artery Disease Outcomes Study (SCS-EPOS). The Research Centre belongs to the Medtronic Company, which is the worldwide manufacturer of the neurostimulators for SCS treatment. Medtronic did not, however, sponsor the preparation of this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>DU identified potentially relevant papers, decided upon eligibility and quality of trials, extracted data, and wrote the review.</P>
<P>HV identified potentially relevant papers, discussed their eligibility with DU, decided upon the quality of trials, and extracted data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Amann-2003" MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="Amann 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amann W, Berg P, Gersbach P, Gamain J, Raphael JH, Ubbink DT</AU>
<TI>Spinal cord stimulation in the treatment of non-reconstructable stable critical leg ischaemia: results of the European peripheral vascular disease outcomes study (SCS-EPOS)</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>3</NO>
<PG>280-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-1996" MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="Claeys 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LG, Horsch S</AU>
<TI>Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation</TI>
<SO>International Angiology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>4</NO>
<PG>344-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESES" MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="ESES" YEAR="1999">
<REFERENCE MODIFIED="2008-10-19 03:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klomp HM, Spincemaille GH, Steyerberg EW, Berger MY, Habbema JD, van Urk H</AU>
<TI>Design issues of a randomised controlled clinical trial on spinal cord stimulation in critical limb ischaemia. ESES Study Group</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>4</NO>
<PG>478-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klomp HM, Spincemaille GH, Steyerberg EW, Habbema JD, Van Urk H</AU>
<TI>Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9158</NO>
<PG>1040-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-19 03:37:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klomp HM, Steyerberg EW, van UH, Habbema JD, ESES Study Group</AU>
<TI>Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>500-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, Klomp HM, Steyerberg EW, Habbema JD</AU>
<TI>Pain and quality of life in patients with critical limb ischaemia: results of a randomized controlled multicentre study on the effect of spinal cord stimulation. ESES study group</TI>
<SO>European Journal of Pain</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>2</NO>
<PG>173-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, Klomp HM, Steyerberg EW, van Urk H, Habbema JD, ESES Study Group</AU>
<TI>Technical data and complications of spinal cord stimulation: data from a randomized trial on critical limb ischemia</TI>
<SO>Stereotactic and Functional Neurosurgery</SO>
<YR>2000</YR>
<VL>74</VL>
<NO>2</NO>
<PG>63-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ubbink DT, Spincemaille GH, Prins MH, Reneman RS, Jacobs MJ</AU>
<TI>Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>2</NO>
<PG>236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jivegard-1995" MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="Jivegard 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-01-23 08:27:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jivegard LE, Augustinsson LE, Holm J, Risberg B, Ortenwall P</AU>
<TI>Effects of spinal cord stimulation (SCS) in patients with inoperable severe lower limb ischaemia: a prospective randomised controlled study</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>421-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spincemaille-2000a" NAME="Spincemaille 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, Klomp HM, Steyerberg EW, Habbema JD</AU>
<TI>Spinal cord stimulation in patients with critical limb ischemia: A preliminary evaluation of a multicentre trial</TI>
<SO>Acta Chirurgica Austriaca</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suy-1994" MODIFIED="2013-01-18 09:55:46 +0000" MODIFIED_BY="[Empty name]" NAME="Suy 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-18 09:55:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Suy R, Gybels J, Van Damme H, Martin D, van Maele R, Delaporte C</AU>
<TI>Spinal cord stimulation for ischemic rest pain. The Belgian randomized study</TI>
<SO>Spinal Cord Stimulation: An innovative method in the treatment of PVD</SO>
<YR>1994</YR>
<PG>197-202</PG>
<ED>Horsch S, Claeys L</ED>
<PB>Springer</PB>
<IDENTIFIERS MODIFIED="2013-01-18 09:55:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-19 03:39:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-1997a" NAME="Claeys 1997a" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LGY, Horsch S</AU>
<TI>Effects of spinal cord stimulation on ischemic inflammatory pain and wound healing in patients with peripheral arterial occlusive disease Fontaine Stage IV</TI>
<SO>Pain Digest</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>4</NO>
<PG>200-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-1997b" NAME="Claeys 1997b" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LG</AU>
<TI>Improvement of microcirculatory blood flow under epidural spinal cord stimulation in patients with nonreconstructible peripheral arterial occlusive disease</TI>
<SO>Artificial Organs</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>3</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-1998b" NAME="Claeys 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LGY, Horsch S</AU>
<TI>Epidural spinal cord stimulation following intravenous prostaglandin E1 therapy in patients with ischaemic pain (peripheral vascular disease Fontaine stage IV). Preliminary results of a controlled randomized study</TI>
<SO>Pain Clinic</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>3</NO>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-1999" NAME="Claeys 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LGY, Horsch S</AU>
<TI>Spinal cord stimulation (SCS) following intravenous prostaglandin E1 (PGE1) therapy in non-reconstructible peripheral vascular disease (PVD): Fontaine stage IV</TI>
<SO>Pain Clinic</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>3</NO>
<PG>235-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guarnera-1994" NAME="Guarnera 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guarnera G, Furgiuele S, Camilli S</AU>
<TI>Spinal cord electric stimulation vs. femoro-distal bypass in critical ischemia of the legs. Preliminary results in a randomized prospective study</TI>
<TO>Elettrostimulazione midollare vs bypass femoro-distale nell'ischemia critica degli arti inferiori</TO>
<SO>Minerva Cardioangiologica</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>5</NO>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palombo-1995" MODIFIED="2008-10-19 03:36:39 +0100" MODIFIED_BY="[Empty name]" NAME="Palombo 1995" YEAR="1993">
<REFERENCE MODIFIED="2008-10-19 03:36:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palombo D, Porta C, Brustia P, Peinetti F, Udini M, Antico A, et al</AU>
<TI>Limb salvage in critical ischemia. Our experience</TI>
<TO>Salvataggio d'arto nell'ischemia critica. Nostra esperienza.</TO>
<SO>Minerva Chirurgica</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>3</NO>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrakis-2000" NAME="Petrakis 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrakis E, Sciacca V</AU>
<TI>Prospective study of transcutaneous oxygen tension (TcPO2) measurement in the testing period of spinal cord stimulation in diabetic patients with critical lower limb ischaemia</TI>
<SO>International Angiology</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>1</NO>
<PG>18-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tallis-1983" MODIFIED="2008-10-19 03:39:16 +0100" MODIFIED_BY="[Empty name]" NAME="Tallis 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-10-19 03:39:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tallis RC, Illis LS, Sedgwick EM</AU>
<TI>Spinal cord stimulation in peripheral vascular disease</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1983</YR>
<VL>46</VL>
<NO>6</NO>
<PG>478-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-19 03:50:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Augustinsson-1985" MODIFIED="2008-09-26 10:06:04 +0100" MODIFIED_BY="[Empty name]" NAME="Augustinsson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Augustinsson LE, Carlsson CA, Holm J, Jivegard L</AU>
<TI>Epidural electrical stimulation in severe limb ischemia. Pain relief, increased blood flow, and a possible limb-saving effect</TI>
<SO>Annals of Surgery</SO>
<YR>1985</YR>
<VL>202</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broseta-1986" MODIFIED="2008-09-26 10:06:09 +0100" MODIFIED_BY="[Empty name]" NAME="Broseta 1986" TYPE="JOURNAL_ARTICLE">
<AU>Broseta J, Barbera J, de Vera JA, Barcia-Salorio JL, Garcia-March G, Gonzalez-Darder J, et al</AU>
<TI>Spinal cord stimulation in peripheral arterial disease. A cooperative study</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1986</YR>
<VL>64</VL>
<NO>1</NO>
<PG>71-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunt-1991" MODIFIED="2008-09-26 10:06:12 +0100" MODIFIED_BY="[Empty name]" NAME="Bunt 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bunt TJ, Holloway GA, Lawrence P, Cherney D, Malone J</AU>
<TI>Experience with epidural spinal stimulation in the treatment of end-stage peripheral vascular disease</TI>
<SO>Seminars in Vascular Surgery</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsson-1983" MODIFIED="2008-09-26 10:06:15 +0100" MODIFIED_BY="[Empty name]" NAME="Carlsson 1983" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson AM</AU>
<TI>Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale</TI>
<SO>Pain</SO>
<YR>1983</YR>
<VL>16</VL>
<NO>1</NO>
<PG>87-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Claeys-1998" MODIFIED="2008-09-26 10:06:21 +0100" MODIFIED_BY="[Empty name]" NAME="Claeys 1998" TYPE="JOURNAL_ARTICLE">
<AU>Claeys LGY, Ktenidis K, Horsch S</AU>
<TI>Effects of spinal cord stimulation on ischemic pain in patients with Buerger's disease</TI>
<SO>Pain Digest</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>138-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1976" MODIFIED="2008-09-26 10:06:25 +0100" MODIFIED_BY="[Empty name]" NAME="Cook 1976" TYPE="JOURNAL_ARTICLE">
<AU>Cook AW, Oygar A, Baggenstos P, Pacheco S, Kleriga E</AU>
<TI>Vascular disease of extremities. Electrical stimulation of spinal cord and posterior roots</TI>
<SO>New York State Journal of Medicine</SO>
<YR>1976</YR>
<VL>76</VL>
<NO>3</NO>
<PG>366-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-1998" MODIFIED="2008-09-26 10:06:27 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 1998" TYPE="JOURNAL_ARTICLE">
<AU>Deeks J</AU>
<TI>When can odds ratios mislead? Odds ratios should be used only in case control studies and logistic regression analyses</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7166</NO>
<PG>1155-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dutch-CC" MODIFIED="2008-09-26 10:06:30 +0100" MODIFIED_BY="[Empty name]" NAME="Dutch CC" TYPE="OTHER">
<AU>Dutch Cochrane Center</AU>
<TI>Therapy checklist (extended version)</TI>
<SO>http://www.amc.uva.nl/EN/OtherOrganisations/dcc/RCT.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiume-1989" MODIFIED="2008-10-19 03:41:03 +0100" MODIFIED_BY="[Empty name]" NAME="Fiume 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fiume D, Palombi M, Sciassa V, Tamorri M</AU>
<TI>Spinal cord stimulation (SCS) in peripheral ischemic pain</TI>
<SO>Pacing and Clinical Electrophysiology</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>4 Part 2</NO>
<PG>698-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fontaine-1954" MODIFIED="2008-09-26 10:06:39 +0100" MODIFIED_BY="[Empty name]" NAME="Fontaine 1954" TYPE="JOURNAL_ARTICLE">
<AU>Fontaine VR, Kim M, Kieny R</AU>
<TI>Surgical treatment for peripheral vascular disease</TI>
<TO>Die chirurgische Behandlung der peripheren Durchblutungsstörungen</TO>
<SO>Helvetica Chirurgica Acta</SO>
<YR>1954</YR>
<VL>5/6</VL>
<PG>491-533</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galley-1994" MODIFIED="2008-09-26 10:06:42 +0100" MODIFIED_BY="[Empty name]" NAME="Galley 1994" TYPE="BOOK_SECTION">
<AU>Galley D, Pavy O, Elharrar C, et al</AU>
<TI>The use of TcpO2 in assessing patients with spinal cord stimulation for peripheral vascular disease of the lower limbs</TI>
<SO>Spinal cord stimulation for peripheral vascular diseases. Advances and controversies</SO>
<YR>1994</YR>
<PG>93-8</PG>
<ED>Herreros J, Lazorthes Y, Boccalon H, et al</ED>
<PB>Editorial libro del ano</PB>
<CY>Madrid, Spain</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gersbach-1997" MODIFIED="2008-10-19 03:44:36 +0100" MODIFIED_BY="[Empty name]" NAME="Gersbach 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gersbach P, Hasdemir MG, Stevens RD, Nachbur B, Mahler F</AU>
<TI>Discriminative microcirculatory screening of patients with refractory limb ischaemia for dorsal column stimulation</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>5</NO>
<PG>464-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horsch-1994" MODIFIED="2008-09-26 10:06:47 +0100" MODIFIED_BY="[Empty name]" NAME="Horsch 1994" TYPE="JOURNAL_ARTICLE">
<AU>Horsch S, Claeys L</AU>
<TI>Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>5</NO>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-1990" MODIFIED="2008-09-26 10:06:49 +0100" MODIFIED_BY="[Empty name]" NAME="Jacobs 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs MJ, Jorning PJ, Beckers RC, Ubbink DT, van Kleef M, Slaaf DW, et al</AU>
<TI>Foot salvage and improvement of microvascular blood flow as a result of epidural spinal cord electrical stimulation</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>3</NO>
<PG>354-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klomp-1999" MODIFIED="2008-09-26 10:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="Klomp 1999" TYPE="JOURNAL_ARTICLE">
<AU>Klomp HM, Spincemaille GHJJ, Steyerberg EW, Habbema JD, Van Urk H</AU>
<TI>Spinal-cord stimulation in critical limb ischaemia: a randomised trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9158</NO>
<PG>1040-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klomp-2006" MODIFIED="2008-10-19 03:43:43 +0100" MODIFIED_BY="[Empty name]" NAME="Klomp 2006" TYPE="JOURNAL_ARTICLE">
<AU>Klomp HM, Steyerberg EW, van UH, Habbema JD, ESES Study Group</AU>
<TI>Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>500-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-1997" MODIFIED="2008-09-26 10:06:57 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kumar K, Toth C, Nath RK, Verma AK, Burgess JJ</AU>
<TI>Improvement of limb circulation in peripheral vascular disease using epidural spinal cord stimulation: a prospective study</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1997</YR>
<VL>86</VL>
<NO>4</NO>
<PG>662-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Linderoth-1992" MODIFIED="2008-09-26 10:07:00 +0100" MODIFIED_BY="[Empty name]" NAME="Linderoth 1992" TYPE="OTHER">
<AU>Linderoth B</AU>
<TI>Dorsal column stimulation and pain: experimental studies on putative neurochemical and neurophysiological mechanisms</TI>
<SO>Thesis. Karolinska Institute, Stockholm</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masters_x002d_Steed-1992" NAME="Masters-Steed 1992" TYPE="JOURNAL_ARTICLE">
<AU>Masters-Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC</AU>
<TI>Chronic-pain medications: equivalent levels and methods of quantifying usage</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>3</NO>
<PG>204-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melzack-1975" MODIFIED="2008-10-19 03:42:53 +0100" MODIFIED_BY="[Empty name]" NAME="Melzack 1975" TYPE="JOURNAL_ARTICLE">
<AU>Melzack R</AU>
<TI>The McGill Pain Questionnaire: major properties and scoring methods</TI>
<SO>Pain</SO>
<YR>1975</YR>
<VL>1</VL>
<NO>3</NO>
<PG>277-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mingoli-1993" MODIFIED="2008-09-26 10:07:05 +0100" MODIFIED_BY="[Empty name]" NAME="Mingoli 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mingoli A, Sciacca V, Tamorri M, Fiume D, Sapienza P</AU>
<TI>Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease</TI>
<SO>Angiology</SO>
<YR>1993</YR>
<VL>44</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rickman-1994" MODIFIED="2008-09-26 10:07:07 +0100" MODIFIED_BY="[Empty name]" NAME="Rickman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rickman S, Wuebbels BH, Holloway GA Jr</AU>
<TI>Spinal cord stimulation for relief of ischemic pain in end-stage arterial occlusive disease</TI>
<SO>Journal of Vascular Nursing</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>1</NO>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiegelmann-1991" MODIFIED="2008-09-26 10:07:09 +0100" MODIFIED_BY="[Empty name]" NAME="Spiegelmann 1991" TYPE="JOURNAL_ARTICLE">
<AU>Spiegelmann R, Friedman WA</AU>
<TI>Spinal cord stimulation: a contemporary series</TI>
<SO>Neurosurgery</SO>
<YR>1991</YR>
<VL>28</VL>
<NO>1</NO>
<PG>65-70; discussion 70-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spincemaille-2000b" MODIFIED="2008-09-26 10:07:15 +0100" MODIFIED_BY="[Empty name]" NAME="Spincemaille 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, Klomp HM, Steyerberg EW, Habbema JD</AU>
<TI>Pain and quality of life in patients with critical limb ischaemia: results of a randomized controlled multicentre study on the effect of spinal cord stimulation. ESES study group</TI>
<SO>European Journal of Pain</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>2</NO>
<PG>173-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spincemaille-2000c" MODIFIED="2008-10-19 03:46:57 +0100" MODIFIED_BY="[Empty name]" NAME="Spincemaille 2000c" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, Klomp HM, Steyerberg EW, van Urk H, Habbema JD. ESES Study Group</AU>
<TI>Technical data and complications of spinal cord stimulation: data from a randomized trial on critical limb ischemia</TI>
<SO>Stereotactic and Functional Neurosurgery</SO>
<YR>2000</YR>
<VL>74</VL>
<NO>2</NO>
<PG>63-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spincemaille-2001" MODIFIED="2008-10-19 03:47:18 +0100" MODIFIED_BY="[Empty name]" NAME="Spincemaille 2001" TYPE="JOURNAL_ARTICLE">
<AU>Spincemaille GH, de Vet HC, Ubbink DT, Jacobs MJ</AU>
<TI>The results of spinal cord stimulation in critical limb ischaemia: a review</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>2</NO>
<PG>99-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TASC-2000a" MODIFIED="2008-10-19 03:48:40 +0100" MODIFIED_BY="[Empty name]" NAME="TASC 2000a" TYPE="JOURNAL_ARTICLE">
<AU>TASC Working Group</AU>
<TI>Management of peripheral arterial disease. TransAtlantic inter-Society Consensus</TI>
<SO>International Angiology</SO>
<YR>2000</YR>
<VL>19 Suppl 1</VL>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TASC-2000b" MODIFIED="2008-10-19 03:49:11 +0100" MODIFIED_BY="[Empty name]" NAME="TASC 2000b" TYPE="JOURNAL_ARTICLE">
<AU>TASC Working Group</AU>
<TI>Management of peripheral arterial disease. TransAtlantic inter-Society Consensus</TI>
<SO>International Angiology</SO>
<YR>2000</YR>
<VL>19 Suppl 1</VL>
<PG>208-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TASC-2000c" MODIFIED="2008-10-19 03:49:36 +0100" MODIFIED_BY="[Empty name]" NAME="TASC 2000c" TYPE="JOURNAL_ARTICLE">
<AU>TASC Working Group</AU>
<TI>Management of peripheral arterial disease. TransAtlantic inter-Society Consensus</TI>
<SO>International Angiology</SO>
<YR>2000</YR>
<VL>19 Suppl 1</VL>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tesfaye-1996" MODIFIED="2008-10-19 03:50:01 +0100" MODIFIED_BY="[Empty name]" NAME="Tesfaye 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tesfaye S, Watt J, Benbow SJ, Pang KA, Mile J, MacFarlane IA</AU>
<TI>Electrical spinal cord stimulation for painful diabetic peripheral neuropathy</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9043</NO>
<PG>1698-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ubbink-1999" MODIFIED="2008-09-26 10:07:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ubbink 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ubbink DT, Spincemaille GH, Prins MH, Reneman RS, Jacobs MJ</AU>
<TI>Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>2</NO>
<PG>236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1998" NAME="Ware 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE Jr, Gandek B</AU>
<TI>Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>11</NO>
<PG>903-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ubbink-2003" MODIFIED="2013-01-18 09:58:49 +0000" MODIFIED_BY="[Empty name]" NAME="Ubbink 2003" TYPE="COCHRANE_REVIEW">
<AU>Ubbink DT, Vermeulen H</AU>
<TI>Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-09-26 10:04:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-26 10:04:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ubbink-2005" MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]" NAME="Ubbink 2005" TYPE="COCHRANE_REVIEW">
<AU>Ubbink DT, Vermeulen H</AU>
<TI>Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-23 08:33:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004001.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-09-29 15:18:16 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-18 10:08:06 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-01-18 10:08:06 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-19 03:21:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amann-2003">
<CHAR_METHODS>
<P>Controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-19 03:21:07 +0100" MODIFIED_BY="[Empty name]">
<P>Country: 17 European centres.<BR/>Number of participants: 112.<BR/>Age: SCS group = 68 ± 13 SD;<BR/>Control group = 67 ± 9 SD.<BR/>Sex: M=75; F=37.<BR/>Inclusion criteria: Non-reconstructable CLI. Fontaine stages III; persistent pain at rest &gt; 2 weeks or ischaemic skin lesions.<BR/>Exclusion criteria: Extensive necrosis; infected gangrene; terminally ill.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-19 03:21:24 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: SCS + best medical therapy (n=73).<BR/>Control group: Best medical therapy (n=39).<BR/>Duration: 18 months follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief, QoL, Fontaine stage, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-19 03:21:37 +0100" MODIFIED_BY="[Empty name]">
<P>TcpO<SUB>2</SUB> selection.<BR/>Test stimulation.<BR/>Raw data available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-18 10:08:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Claeys-1996">
<CHAR_METHODS>
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany.<BR/>Number of participants: 86.<BR/>Age: SCS group = 67.7 ± 11.9 SD; <BR/>Control group = 69.9 ± 10.2 SD.<BR/>Sex: M=49; F=37.<BR/>Inclusion criteria: Non-reconstructable CLI; Fontaine stage IV; ulcers or gangrene present for minimum of 3 weeks; ankle pressure &lt; 50mmHg.<BR/>Exclusion criteria: Mixed type of ulceration; local infection; patients suitable for reconstructive procedures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-18 10:08:06 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment group: SCS + PGE1 (n=45).<BR/>Control group: Conservative medical therapy - PGE1 (n=41).<BR/>Duration: 1 year follow up.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief, ABPI,<BR/>Fontaine stage, ulcer healing, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-19 03:22:38 +0100" MODIFIED_BY="[Empty name]">
<P>TcpO<SUB>2</SUB>.<BR/>Test stimulation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-19 03:23:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ESES">
<CHAR_METHODS MODIFIED="2008-10-19 03:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. Randomisation by random-numbers table, stratified by diabetes, ankle pressure, and hospital. Treatment allocation performed in an independent institute.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: The Netherlands, 17 centres.<BR/>Number of participants: 120.<BR/>Age: SCS group = 73.1 ± 9.8 SD;<BR/>Control group = 721.1 ± 10.6 SD.<BR/>Sex: M=70; F=50.<BR/>Inclusion criteria: Non-reconstructable CLI, persistent pain at rest &gt; 2 weeks or ischaemic skin lesions, ankle systolic pressure &lt; 50mmHg.<BR/>Exclusion criteria: Extensive necrosis, infected gangrene, terminally ill.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group: SCS + best medical therapy (n=60).<BR/>Control group: Best medical therapy (n=60).<BR/>Duration: 2 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief, Fontaine stage, <BR/>QoL, ABPI<BR/>complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-19 03:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>TcpO<SUB>2</SUB> selection.<BR/>Raw data available in Ubbink 1999b reference.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-19 03:24:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jivegard-1995">
<CHAR_METHODS>
<P>Randomised controlled trial. Method of randomisation: unsure.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-19 03:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden, 2 university hospitals.<BR/>Number of participants: 51.<BR/>Age: SCS group = 73 ± 12 SD;<BR/>Control group = 73 ± 12 SD.<BR/>Inclusion criteria: Severe chronic (&gt; 2 weeks duration) lower limb ischaemia. non-reconstructable CLI.<BR/>Exclusion criteria: Rapidly progressing ischaemia, gangrene of more than one toe, extensive infection and/or non-healing ischaemic ulcerations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-19 03:24:43 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: SCS + oral analgesics (n=25).<BR/>Control group: Oral analgesic (n=26).<BR/>Duration: 18 months follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief, ABPI, toe pressure, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-18 09:53:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spincemaille-2000a">
<CHAR_METHODS>
<P>Randomised controlled trial (preliminary results).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-19 03:25:05 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands.<BR/>Number of participants: 37.<BR/>Age: SCS group: 72; Control group: 70. Range: 56 to 87.<BR/>Sex: M=28; F=9.<BR/>Inclusion criteria: Non-reconstructable CLI; persistent pain at rest, or ischaemic skin lesions.<BR/>Exclusion criteria: infected gangrene, terminally ill, ulcer surface &gt; 3 cm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-18 09:53:47 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment group: SCS+ best medical therapy (n=19).<BR/>Control group: Best medical therapy: analgesic and vasoactive drugs (n=18).<BR/>Duration: 2 years.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-19 03:25:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suy-1994">
<CHAR_METHODS>
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-19 03:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium, 3 university hospitals.<BR/>Number of participants: 38.<BR/>Age: SCS group 66 ± 11 SD;<BR/>Control group 65 ± 9 SD.<BR/>Inclusion criteria: chronic ischaemic pain related to PAOD; non-reconstructable CLI (n=27) and Buerger (n=11 excluded).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-19 03:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: SCS (n=20).<BR/>Control group: Conservative therapy (n=18).<BR/>Duration: follow up 20 ± 15 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Limb survival, pain relief, <BR/>Fontaine stage, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABPI: Ankle Brachial Pressure Index<BR/>Hg: Mercury<BR/>CLI: Critical limb ischaemia<BR/>PGE1: Prostaglandin E1<BR/>QoL: Quality of life<BR/>SCS: Spinal cord stimulation<BR/>TcpO<SUB>2</SUB>: Transcutaneous oxygen pressure<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-09-29 15:17:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Claeys-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Claeys-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Claeys-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Claeys-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guarnera-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inclusion of reconstructable CLI patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Palombo-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petrakis-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tallis-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-26 09:32:46 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-26 09:32:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-26 09:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amann-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-26 09:32:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-ESES">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jivegard-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Spincemaille-2000a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Suy-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-19 03:27:23 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-19 03:27:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Costs</TITLE>
<TABLE COLS="3" ROWS="10">
<TR>
<TH>
<P>Costs (Euros)</P>
</TH>
<TH>
<P>SCS (Euros)</P>
</TH>
<TH>
<P>Conservative (Euros)</P>
</TH>
</TR>
<TR>
<TD>
<P>Hospitalisation</P>
</TD>
<TD>
<P>11,779</P>
</TD>
<TD>
<P>12,321</P>
</TD>
</TR>
<TR>
<TD>
<P>Rehabilitation</P>
</TD>
<TD>
<P>6748</P>
</TD>
<TD>
<P>7471</P>
</TD>
</TR>
<TR>
<TD>
<P>Operative procedures</P>
</TD>
<TD>
<P>8362</P>
</TD>
<TD>
<P>417</P>
</TD>
</TR>
<TR>
<TD>
<P>Stimulator implant</P>
</TD>
<TD>
<P>7215</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Professional home care</P>
</TD>
<TD>
<P>Equal</P>
</TD>
<TD>
<P>Equal</P>
</TD>
</TR>
<TR>
<TD>
<P>Outpatient costs</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
</TR>
<TR>
<TD>
<P>Medication</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
</TR>
<TR>
<TD>
<P>Non-medical</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
<TD>
<P>Negligible</P>
</TD>
</TR>
<TR>
<TD>
<P>TOTAL</P>
</TD>
<TD>
<P>36,502</P>
</TD>
<TD>
<P>28,617</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-09-26 09:43:14 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-09-26 09:38:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Limb survival</NAME>
<DICH_OUTCOME CHI2="1.6326100130378731" CI_END="-0.020647647614356737" CI_START="-0.19929600040984552" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.10997182401210114" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-09-26 09:37:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8972780294366731" P_Q="1.0" P_Z="0.015821053330927235" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="195" WEIGHT="100.0" Z="2.413017651773593">
<NAME>Amputations (12 months)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Conservative</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.013915335987122746" CI_START="-0.36164979331062125" EFFECT_SIZE="-0.17386722866174925" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.09580919145967828" STUDY_ID="STD-Amann-2003" TOTAL_1="73" TOTAL_2="39" VAR="0.00917940116815729" WEIGHT="24.121887474686567"/>
<DICH_DATA CI_END="0.12145558775532525" CI_START="-0.20058837908323854" EFFECT_SIZE="-0.039566395663956644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.08215558280121611" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="0.006749539785407476" WEIGHT="20.358218066219163"/>
<DICH_DATA CI_END="0.09373763879580499" CI_START="-0.2604043054624716" EFFECT_SIZE="-0.08333333333333331" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0903439928110167" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.008162037037037037" WEIGHT="28.46840249910322"/>
<DICH_DATA CI_END="0.12896094239991962" CI_START="-0.40896094239991965" EFFECT_SIZE="-0.14" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.13722749219957572" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" VAR="0.018831384615384618" WEIGHT="12.094419362364112"/>
<DICH_DATA CI_END="0.12729927694461313" CI_START="-0.4957203295761921" EFFECT_SIZE="-0.1842105263157895" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.15893649358740886" STUDY_ID="STD-Spincemaille-2000a" TOTAL_1="19" TOTAL_2="18" VAR="0.02526080899386046" WEIGHT="8.77134563485883"/>
<DICH_DATA CI_END="0.3127236987364408" CI_START="-0.4149964260091681" EFFECT_SIZE="-0.051136363636363646" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.18564630026004875" STUDY_ID="STD-Suy-1994" TOTAL_1="16" TOTAL_2="11" VAR="0.034464548800244174" WEIGHT="6.185726962768107"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-09-26 09:38:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Amputation rate in non-hypertensives (18 months)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.05596861056453334" CI_START="-0.7831922285963058" EFFECT_SIZE="-0.4195804195804196" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="0.18551963805662236" STUDY_ID="STD-Jivegard-1995" TOTAL_1="11" TOTAL_2="13" VAR="0.03441753610466017" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-09-26 09:41:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Pain relief</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="84" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in VAS score (0-100; where 100 is worst) after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-24.2" MEAN_2="-21.5" ORDER="8" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-ESES" TOTAL_1="57" TOTAL_2="58" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-33.0" MEAN_2="-13.0" ORDER="9" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2008-09-26 09:41:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="60" TOTAL_2="60" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Pain Rating Index (overall; where higher is worse) after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-11.5" MEAN_2="-13.0" ORDER="10" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2008-09-26 09:41:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in VAS score (0-100; where 100 is worst) after 3 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="4.7" MEAN_2="1.5" ORDER="11" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Spincemaille-2000a" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Clinical improvement</NAME>
<DICH_OUTCOME CHI2="0.3725806939392149" CI_END="0.4696879036755489" CI_START="0.19155677822808226" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.3306223409518156" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.3281906244763367" LOG_CI_START="-0.7177024759180718" LOG_EFFECT_SIZE="-0.48066780344371796" METHOD="MH" NO="1" P_CHI2="0.5416012058287996" P_Q="1.0" P_Z="3.1662546601868274E-6" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="4.659729325204751">
<NAME>Reaching Fontaine stage II</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4719585683883881" CI_START="0.13291948039209978" EFFECT_SIZE="0.30243902439024395" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" O_E="0.0" SE="0.0864911525595841" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="0.007480719471085253" WEIGHT="69.36776491540516"/>
<DICH_DATA CI_END="0.6367989800657814" CI_START="0.15208990882310755" EFFECT_SIZE="0.3944444444444445" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" O_E="0.0" SE="0.1236525454207315" STUDY_ID="STD-Suy-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.015289951989026064" WEIGHT="30.632235084594832"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.767681907325457" CI_END="0.3761641080616927" CI_START="-0.23751674286415575" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06932368259876848" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="35" I2="85.2238918185918" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.4246226452938318" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.1591183748409286" METHOD="MH" NO="2" P_CHI2="0.009282383245081238" P_Q="1.0" P_Z="0.6579033774938037" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.041793700501130064" TOTALS="YES" TOTAL_1="105" TOTAL_2="101" WEIGHT="99.99999999999997" Z="0.44280971441192907">
<NAME>Reaching Fontaine stage III</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3702849662538864" CI_START="0.061151348109257125" EFFECT_SIZE="0.21571815718157178" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="14" O_E="0.0" SE="0.07886206598259862" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="0.006219225451043738" WEIGHT="51.04706740275991"/>
<DICH_DATA CI_END="0.09493881235581514" CI_START="-0.26160547902248177" EFFECT_SIZE="-0.08333333333333331" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" O_E="0.0" SE="0.09095684772543597" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.008273148148148148" WEIGHT="48.95293259724007"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10862924694616968" CI_END="-0.3499177687614583" CI_START="-0.7313005053502168" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.5406091370558376" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="3" P_CHI2="0.7417101848707222" P_Q="0.7424602136199544" P_Z="2.7525548816044954E-8" Q="0.10797610871195168" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="38" WEIGHT="100.00000000000001" Z="5.556488727413211">
<NAME>Ulcer healing and hypertension</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.33018525186884173" CI_START="-0.8031480814644916" DF="0" EFFECT_SIZE="-0.5666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="2.645953946706246E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="60.913705583756354" Z="4.696547755583904">
<NAME>Hypertensives</NAME>
<DICH_DATA CI_END="-0.33018525186884173" CI_START="-0.8031480814644916" EFFECT_SIZE="-0.5666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16" O_E="0.0" SE="0.12065600014243125" STUDY_ID="STD-Claeys-1996" TOTAL_1="20" TOTAL_2="24" VAR="0.01455787037037037" WEIGHT="60.913705583756354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.18031852706711016" CI_START="-0.8196814729328898" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.002173099305052592" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="39.08629441624366" Z="3.0654951107402866">
<NAME>Non-hypertensives</NAME>
<DICH_DATA CI_END="-0.18031852706711016" CI_START="-0.8196814729328898" EFFECT_SIZE="-0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" O_E="0.0" SE="0.1631057894198549" STUDY_ID="STD-Suy-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.026603498542274052" WEIGHT="39.08629441624366"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Ankle/brachial index</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="67" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Ankle/brachial pressure index increase after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.03" MEAN_2="-0.58" ORDER="18" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.03" MEAN_2="0.02" ORDER="19" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-09-26 09:43:14 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Quality of life</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.197261384356578" CI_START="-0.1972613843565778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.10162225019695392" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="87" UNITS="" WEIGHT="100.0" Z="1.6370393384009139">
<NAME>Nottingham Health Profile (0-100; where 100 is worst) after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Mobility score amputees</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="61.2" MEAN_2="57.0" ORDER="20" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-ESES" TOTAL_1="29" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.197261384356578" CI_START="-0.1972613843565778" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="1.0" P_Z="0.10162225019695392" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.6370393384009139">
<NAME>Overall</NAME>
<CONT_DATA CI_END="2.197261384356578" CI_START="-0.1972613843565778" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="34.0" ORDER="21" SD_1="2.6" SD_2="3.0" SE="0.6108588697549663" STUDY_ID="STD-ESES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Mobility score non-amputees</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="40.0" MEAN_2="50.5" ORDER="22" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-ESES" TOTAL_1="29" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2008-09-26 09:43:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Euroqol (0-100; where 100 is worst) after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="41.0" MEAN_2="43.0" ORDER="23" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-ESES" TOTAL_1="56" TOTAL_2="58" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>TcpO2</NAME>
<CONT_OUTCOME CHI2="16.299430646946078" CI_END="18.43799007547287" CI_START="-15.657216403720907" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3903868358759814" ESTIMABLE="YES" I2="93.86481637512065" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="5.408061471701142E-5" P_Q="1.0" P_Z="0.8729969837305602" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="142.09255902865766" TOTALS="YES" TOTAL_1="101" TOTAL_2="96" UNITS="" WEIGHT="100.0" Z="0.15985285934892307">
<NAME>TcpO2 after 12 months</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.690783081573823" CI_START="5.109216918426178" EFFECT_SIZE="9.9" ESTIMABLE="YES" MEAN_1="21.3" MEAN_2="11.4" ORDER="24" SD_1="12.7" SD_2="9.9" SE="2.4443219974259263" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" WEIGHT="51.09417721767806"/>
<CONT_DATA CI_END="-0.542770555214946" CI_START="-14.457229444785053" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="32.3" MEAN_2="39.8" ORDER="25" SD_1="22.07" SD_2="14.65" SE="3.549672085641773" STUDY_ID="STD-ESES" TOTAL_1="56" TOTAL_2="55" WEIGHT="48.90582278232195"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Complications</NAME>
<DICH_OUTCOME CHI2="13.861456947598995" CI_END="0.2041757034970237" CI_START="0.044198388635839844" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="0.12418704606643177" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="0" I2="63.92875569356313" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.6899959393547456" LOG_CI_START="-1.3545935636671875" LOG_EFFECT_SIZE="-0.9059237029941549" METHOD="MH" NO="1" P_CHI2="0.01651387317249431" P_Q="1.0" P_Z="0.00234264904410053" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0061539126816038845" TOTALS="YES" TOTAL_1="210" TOTAL_2="202" WEIGHT="100.0" Z="3.0429581575091285">
<NAME>Change in stimulation requiring reintervention (within 12 months)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40747536447873633" CI_START="0.1291100013749222" EFFECT_SIZE="0.2682926829268293" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.07101287709864176" STUDY_ID="STD-Amann-2003" TOTAL_1="41" TOTAL_2="39" VAR="0.005042828713826801" WEIGHT="14.875411385321259"/>
<DICH_DATA CI_END="0.1500120213458846" CI_START="-0.016678688012551263" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27" O_E="0.0" SE="0.042523921529495155" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="0.0018082839022466619" WEIGHT="20.918365011221606"/>
<DICH_DATA CI_END="0.3037892903468779" CI_START="0.0962107096531221" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.052954692619637186" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.0028041994704402573" WEIGHT="18.592771736406668"/>
<DICH_DATA CI_END="0.1430443338871675" CI_START="-0.06304433388716749" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="29" O_E="0.0" SE="0.05257460580906999" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" VAR="0.002764089175979096" WEIGHT="18.67639602367482"/>
<DICH_DATA CI_END="0.3393088919694809" CI_START="-0.023519418285270377" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.09255994322260375" STUDY_ID="STD-Spincemaille-2000a" TOTAL_1="19" TOTAL_2="18" VAR="0.00856734308937163" WEIGHT="11.313989582360913"/>
<DICH_DATA CI_END="0.181580592225561" CI_START="-0.08158059222556101" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" O_E="0.0" SE="0.06713418882359672" STUDY_ID="STD-Suy-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.004506999309002338" WEIGHT="15.62306626101473"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2995943616099357" CI_END="0.06065675137361947" CI_START="-0.0033467834771981828" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="0.028654983948210644" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-1.2171208531465434" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5427998304868282" METHOD="MH" NO="2" P_CHI2="0.6539038527357219" P_Q="1.0" P_Z="0.07926126038697182" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="210" TOTAL_2="202" WEIGHT="100.0" Z="1.7549885845203046">
<NAME>Infection requiring removal</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12818849986306757" CI_START="-0.03062752425331146" EFFECT_SIZE="0.04878048780487805" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.04051503633972347" STUDY_ID="STD-Amann-2003" TOTAL_1="41" TOTAL_2="39" VAR="0.0016414681696091135" WEIGHT="19.423629346956442"/>
<DICH_DATA CI_END="0.044426760041579326" CI_START="-0.044426760041579326" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.022667130820776267" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="5.137988196461853E-4" WEIGHT="20.848260479738578"/>
<DICH_DATA CI_END="0.1125934423185589" CI_START="-0.012593442318558898" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="0.031936016586165863" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.001019909155391861" WEIGHT="29.153665061097847"/>
<DICH_DATA CI_END="0.07329821857555005" CI_START="-0.07329821857555005" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" O_E="0.0" SE="0.03739773748585027" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" VAR="0.0013985907690605703" WEIGHT="12.385543980204966"/>
<DICH_DATA CI_END="0.09930932864748786" CI_START="-0.09930932864748786" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.05066895587410134" STUDY_ID="STD-Spincemaille-2000a" TOTAL_1="19" TOTAL_2="18" VAR="0.0025673430893716287" WEIGHT="8.98248058639231"/>
<DICH_DATA CI_END="0.181580592225561" CI_START="-0.08158059222556101" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="37" O_E="0.0" SE="0.06713418882359672" STUDY_ID="STD-Suy-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.004506999309002338" WEIGHT="9.206420545609845"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.518586356927669" CI_END="0.0723185719984633" CI_START="0.004209798786918559" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="0.03826418539269093" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="33.498136981655186" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-1.1407501580209463" LOG_CI_START="-2.3757386613660616" LOG_EFFECT_SIZE="-1.417207527943441" METHOD="MH" NO="3" P_CHI2="0.18483947591467575" P_Q="1.0" P_Z="0.027647338072313225" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="210" TOTAL_2="202" WEIGHT="100.00000000000001" Z="2.202254474162974">
<NAME>Battery: end of life</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.22962817573105995" CI_START="0.014274263293330286" EFFECT_SIZE="0.12195121951219512" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.05493823206355164" STUDY_ID="STD-Amann-2003" TOTAL_1="41" TOTAL_2="39" VAR="0.0030182093422686535" WEIGHT="19.423629346956446"/>
<DICH_DATA CI_END="0.044426760041579326" CI_START="-0.044426760041579326" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.022667130820776267" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="5.137988196461853E-4" WEIGHT="20.84826047973858"/>
<DICH_DATA CI_END="0.1125934423185589" CI_START="-0.012593442318558898" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40" O_E="0.0" SE="0.031936016586165863" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.001019909155391861" WEIGHT="29.153665061097854"/>
<DICH_DATA CI_END="0.07329821857555005" CI_START="-0.07329821857555005" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="41" O_E="0.0" SE="0.03739773748585027" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" VAR="0.0013985907690605703" WEIGHT="12.38554398020497"/>
<DICH_DATA CI_END="0.09930932864748786" CI_START="-0.09930932864748786" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" O_E="0.0" SE="0.05066895587410134" STUDY_ID="STD-Spincemaille-2000a" TOTAL_1="19" TOTAL_2="18" VAR="0.0025673430893716287" WEIGHT="8.982480586392311"/>
<DICH_DATA CI_END="0.09711982503294672" CI_START="-0.09711982503294672" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.049551841665977286" STUDY_ID="STD-Suy-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.0024553850124900824" WEIGHT="9.206420545609848"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.156304243534905" CI_END="0.32720868123293556" CI_START="0.027554690329107512" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.17738168578102154" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="0" I2="87.93592925610835" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-0.4851751825021037" LOG_CI_START="-1.5598044653902987" LOG_EFFECT_SIZE="-0.7510912220174367" METHOD="MH" NO="4" P_CHI2="1.1096266852028691E-6" P_Q="1.0" P_Z="0.020318110697788102" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02524039517128308" TOTALS="YES" TOTAL_1="191" TOTAL_2="184" WEIGHT="100.00000000000003" Z="2.3204210602980595">
<NAME>Overall complications requiring re-intervention</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5930607961104861" CI_START="0.2849879843773187" EFFECT_SIZE="0.43902439024390244" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="0.07859144712943873" STUDY_ID="STD-Amann-2003" TOTAL_1="41" TOTAL_2="39" VAR="0.006176615561899363" WEIGHT="18.600263580659885"/>
<DICH_DATA CI_END="0.1500120213458846" CI_START="-0.016678688012551263" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" O_E="0.0" SE="0.042523921529495155" STUDY_ID="STD-Claeys-1996" TOTAL_1="45" TOTAL_2="41" VAR="0.0018082839022466619" WEIGHT="21.604185511797592"/>
<DICH_DATA CI_END="0.38041422509628137" CI_START="0.15291910823705196" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.05803553500311277" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.003368123323097528" WEIGHT="20.426247541213893"/>
<DICH_DATA CI_END="0.1430443338871675" CI_START="-0.06304433388716749" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="47" O_E="0.0" SE="0.05257460580906999" STUDY_ID="STD-Jivegard-1995" TOTAL_1="25" TOTAL_2="26" VAR="0.002764089175979096" WEIGHT="20.866825230822137"/>
<DICH_DATA CI_END="0.2560930650150642" CI_START="-0.05609306501506417" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.07964078230330064" STUDY_ID="STD-Suy-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.0063426542058817245" WEIGHT="18.502478135506504"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.360844499813966" CI_END="0.23060526414964339" CI_START="-0.06233785982198768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08413370216382786" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="86.414602291554" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="-0.6371307830558567" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0750300002565505" METHOD="MH" NO="5" P_CHI2="0.006665980523791859" P_Q="1.0" P_Z="0.26024632465890774" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009697202719986902" TOTALS="YES" TOTAL_1="135" TOTAL_2="97" WEIGHT="100.00000000000003" Z="1.1258091597541047">
<NAME>Initial implantation problems (not included in overall complications)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08070952860124113" CI_START="-0.02737619526790779" EFFECT_SIZE="0.02666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="49" O_E="0.0" SE="0.027573395409741023" STUDY_ID="STD-Amann-2003" TOTAL_1="75" TOTAL_2="37" VAR="7.602921344219273E-4" WEIGHT="53.405106353653096"/>
<DICH_DATA CI_END="0.2437661564839066" CI_START="0.056233843516093396" EFFECT_SIZE="0.15" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.04784075484219204" STUDY_ID="STD-ESES" TOTAL_1="60" TOTAL_2="60" VAR="0.0022887378238707207" WEIGHT="46.594893646346925"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2013-01-18 09:54:37 +0000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-01-18 09:54:37 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Klomp, October 2004</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>22 October 2004<BR/>This review [1] was recently published as well in the British Journal of Surgery [2], but contains major problems. The review describes 6 studies, with patient numbers varying from 27 to 120 patients. One (randomised) study was never reviewed (Suy), one study was NOT randomised (Amann), one study was stopped prematurely (Spincemaille), and for at least three studies concealment of treatment allocation was dubious. The selected data for the "amputation rate after 12 months" are incorrect for our study [3], and the use of data from a subgroup in the smallest study (Suy) is unjustifiable.</P>
<P>At least the choices made in the process should be adequately described. Presently, the debatable choices of data input (non-randomised data, subgroup-data) are not properly addressed in the methodological or discussion sections. </P>
<P>The same meta-analysis, performed with the, in our view proper amputation data input of 5 randomised studies, generates a risk difference of -0.07 (95% CI: -0.17 to +0.03) instead of -0.13 (95% CI: -0.22 to -0.04). The main conclusion, that spinal cord stimulation is better than conservative treatment alone in achieving a reduction in amputation risk, is not justified. If SCS is beneficial, the magnitude of the effect is very small. </P>
<P>We think that the issues are of such relevance that they should at least be available to users of the Cochrane library who read the Ubbink review of SCS treatment. So modifications are required in the present Cochrane review [4,5]. </P>
<P>Houke Klomp, Amsterdam<BR/>Ewout Steyerberg, Rotterdam</P>
<P>References<BR/>1.Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2003:CD004001.</P>
<P>2.Ubbink DT, Vermeulen H, Spincemaille GH, Gersbach PA, Berg P, Amann W. Systematic review and meta-analysis of controlled trials assessing spinal cord stimulation for inoperable critical leg ischaemia. Br J Surg. 2004;91:948-55.</P>
<P>3.Klomp HM, Spincemaille GH, Steyerberg EW, Habbema JD, van Urk H. Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. Lancet. 1999;353:1040-4.</P>
<P>4.Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama. 1995;273:408-12.</P>
<P>5.Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-13.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-01-18 09:54:37 +0000" MODIFIED_BY="[Empty name]">
<P>4 November 2004<BR/>We do not agree with the comment that our review would contain major problems and improper descriptions of our methodology for the following reasons:</P>
<P>1.The methodological quality and validity of every trial was judged according to standards supplied by the Dutch Cochrane Centre (while DU was replaced as author when judging trials of which he was co-author). This implies that even the non-peer-reviewed paper by Suy et al. was methodologically checked by independent authors. This has also been mentioned in the 'Methods of the review' section.</P>
<P>2.The trials we included in our study were defined beforehand, as stated in the 'Criteria For Considering Studies For This Review', under 'Types of studies', which comprised controlled clinical trials, including the motivation for this. Because we are aware of the possible effects of including non-randomised data, we have conducted a sensitivity analysis, as mentioned in the Results section under 'Limb salvage': Excluding this trial (Amann study) did not influence the results substantially. The Spincemaille study stopped prematurely, probably because the Dutch multicenter study was about to start, which they joined. This is no reason for excluding the study from our meta-analysis.</P>
<P>3.We have checked with the commenter the data regarding the ESES trial she disagreed with. Instead of the 27 versus 32 amputations at 12 months we present, she mentioned 24 versus 29 amputations, which was not apparent from the Lancet paper. We repeated the meta-analysis with these data and found that this does not alter the results, but we will correct these data in the next update of our review.</P>
<P>4.The smallest trial by Suy et al. included patients with non-reconstructable critical leg ischaemia as well as Buerger's disease. In order not to compromise homogeneity of the patients in this meta-analysis, only CLI patients were included, which has been addressed in the 'Description of studies' section. Again, we re-analysed the data after excluding these (few) data from the meta-analysis. This did not influence limb salvage risk difference significantly.</P>
<P>5.The same meta-analysis, performed with the adapted amputation data from six controlled trials generates a risk difference of -0.11 (95% CI: -0.20 to -0.02).</P>
<P>6.In general, systematic reviews offer the highest level of evidence available, even if not all available studies confirm concealment of allocation. This evidence supports the beneficial effect of SCS. We agree that the magnitude of this effect may appear small, but to us, a risk difference of around 10% as to major amputations within one year seems clinically relevant. Even if the confidence interval would cross zero, one should be careful to conclude there is no effect (Alderson P, Chalmers I. Survey of claims of no effect in abstracts of Cochrane reviews. BMJ. 2003; 326(7387): 475).</P>
<P>Dirk Ubbink and Hester Vermeulen, November 2004.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comments by:<BR/>Houke Klomp, Amsterdam and Ewout Steyerberg, Rotterdam</P>
<P>Response to comments by:<BR/>Dirk Ubbink and Hester Vermeulen, Amsterdam</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-01-23 08:22:41 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-01-23 08:22:41 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-23 08:22:41 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-17 11:04:49 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="37">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>890</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>382</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>753</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>710</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>751</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2146</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>379</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>MeSH descriptor: [Leg] explode all trees and with qualifiers: [Blood supply - BS]</P>
</TD>
<TD ALIGN="RIGHT">
<P>1069</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>719</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>250</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>151</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MeSH descriptor: [Tibial Arteries] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD) </P>
</TD>
<TD ALIGN="RIGHT">
<P>16775</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>4842</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1368</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>706</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>974</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1352</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>peripheral near/3 dis* </P>
</TD>
<TD ALIGN="RIGHT">
<P>3203</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>arteriopathic </P>
</TD>
<TD ALIGN="RIGHT">
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(claudic* or hinken*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1427</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(isch* or CLI) </P>
</TD>
<TD ALIGN="RIGHT">
<P>16663</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>dysvascular* </P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>176</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>227</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>136</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoro* or fempop* or crural) near/3 (obstruct* or occlus*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>324</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 </P>
</TD>
<TD ALIGN="RIGHT">
<P>39111</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>MeSH descriptor: [Electric Stimulation Therapy] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>4045</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>spin* near stimulat* </P>
</TD>
<TD ALIGN="RIGHT">
<P>388</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>column* near stimulat* </P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>epidur* near stimulat* </P>
</TD>
<TD ALIGN="RIGHT">
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>MeSH descriptor: [Electric Stimulation] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>1460</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>#31 or #32 or #33 or #34 or #35 </P>
</TD>
<TD ALIGN="RIGHT">
<P>5657</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>#30 and #36 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>427</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-09-25 14:28:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-09-25 14:27:39 +0100" MODIFIED_BY="[Empty name]">Keywords used in search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-25 14:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>Spinal cord stimulation<BR/>Dorsal column stimulation<BR/>Epidural spinal stimulation<BR/>Epidural electrical stimulation</P>
<P>Critical limb isch(a)emia<BR/>Lower limb isch(a)emia<BR/>Leg isch(a)emia<BR/>Peripheral vascular disease<BR/>Peripheral arterial (occlusive) disease<BR/>Atherosclerosis</P>
<P>Non-reconstructable<BR/>Intractable<BR/>Inoperable</P>
<P>Limb salvage<BR/>Amputation<BR/>Pain relief<BR/>Wound / ulcer healing<BR/>Quality of life<BR/>Complications<BR/>Cost</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>